Tosse (FR)
{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~20 mi. (Bayonne, France, +192 more cities)
facility
Centre Hospitalier de la Côte Basque
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
~20 mi. (Bayonne, France, +197 more cities)
facility
Centre Hospitalier de la Cote /ID# 216185
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
condition
Acute Myeloid Leukemia
drug
azacitidine, +1 more drug
drug type
chemotherapy
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
city
~20 mi. (Bayonne, France, +107 more cities)
facility
Centre Hospitalier de la Côte Basque
condition
Prostate Adenocarcinoma
drug
abemaciclib, +2 more drugs
drug type
hormone therapy, +1 more type
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~56 mi. (Donostia / San Sebastián, Spain, +137 more cities)
facility
Onkologikoa - Instituto Oncologico de San Sebastian ( Site 1258)
condition
Skin Squamous Cell Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
city
~75 mi. (Pau, France, +67 more cities)
facility
Centre Hospitalier de Pau ( Site 1016)
condition
Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition
drug
carboplatin, +5 more drugs
drug type
chemotherapy, +1 more type
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
city
~84 mi. (Pamplona, Spain, +89 more cities)
facility
Complejo Hospitalario de Navarra; Servicio de Farmacia
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
giredestrant, +1 more drug
drug type
hormone therapy
Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer
city
~84 mi. (Pamplona, Spain, +153 more cities)
facility
Complejo Hospitalario de Navarra
condition
Bladder Urothelial Carcinoma, +2 more conditions
drug
BCG solution, +1 more drug
drug type
immunotherapy